Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1661-1670 of 1,873) with videos related to

Pageof 188
Sort By:
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
BMC Cardiovascular Disorders|February 14, 2022
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging studyAshutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 14, 2025
High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1Adam Femerling Langhoff, Niklas Dyrby Johansen, Daniel Modin, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
JAMA Cardiology|May 29, 2024
Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart FailureJohn W Ostrominski, Stephen J Greene, Ravi B Patel, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Pageof 188

Showing results (1661-1670 of 1,873) with videos related to

Sort By:
Pageof 188
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
BMC Cardiovascular Disorders|February 14, 2022
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging studyAshutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 14, 2025
High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1Adam Femerling Langhoff, Niklas Dyrby Johansen, Daniel Modin, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
JAMA Cardiology|May 29, 2024
Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart FailureJohn W Ostrominski, Stephen J Greene, Ravi B Patel, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Pageof 188